<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2016-418-423</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2271</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Профиль аутоантител при системной склеродермии</article-title><trans-title-group xml:lang="en"><trans-title>Profile of autoantibodies in systemic sclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Старовойтова</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Starovoitova</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><email xlink:type="simple">mayyastar@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Десинова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Desinova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koneva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Овсянникова</surname><given-names>О. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ovsyannikova</surname><given-names>O. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алекперов</surname><given-names>Р. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekperov</surname><given-names>R. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черкасова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cherkasova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александрова</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrova</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ананьева</surname><given-names>Л. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Ananyeva</surname><given-names>L. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>19</day><month>10</month><year>2016</year></pub-date><volume>54</volume><issue>4</issue><fpage>418</fpage><lpage>423</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Старовойтова М.Н., Десинова О.В., Конева О.А., Овсянникова О.Б., Алекперов Р.Т., Черкасова М.В., Александрова Е.Н., Ананьева Л.П., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Старовойтова М.Н., Десинова О.В., Конева О.А., Овсянникова О.Б., Алекперов Р.Т., Черкасова М.В., Александрова Е.Н., Ананьева Л.П.</copyright-holder><copyright-holder xml:lang="en">Starovoitova M.N., Desinova O.V., Koneva O.A., Ovsyannikova O.B., Alekperov R.T., Cherkasova M.V., Aleksandrova E.N., Ananyeva L.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2271">https://rsp.mediar-press.net/rsp/article/view/2271</self-uri><abstract><p>Цель – определение частоты выявления аутоантител в когорте российских пациентов с системной склеродермией (ССД), изучение клинических ассоциаций выявленных антител.</p><sec><title>Материал и методы</title><p>Материал и методы. C 2012 по 2015 г. в исследование было включено 300 больных (58 мужчин и 242 женщины), соответствующих критериям ССД Американской коллегии ревматологов / Европейской антиревматической лиги (ACR/EULAR). Всем пациентам проводилось иммунологическое обследование, включающее определение антинуклеарных антител, антител к топоизомеразе I (анти-Scl-70), к центромерам (АЦА), к рибонуклеопротеинам (анти-UI-РНП), к рибонуклеопротеазе III (анти-РНКП III).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Подавляющее большинство больных были женского пола, среднего возраста, с умеренной длительностью заболевания. Преобладали пациенты с лимитированной формой (55,3%), 37,4% больных имели диффузную, 5,9% – перекрестную (overlap-синдром); &lt;1% – висцеральную и ювенильную формы ССД. У подавляющего большинства (83,8%) пациентов обнаружен антинуклеарный фактор. Наиболее часто из ССД-ассоциированных антител (приблизительно у половины пациентов) были выявлены анти Scl-70. АЦА имели место лишь у 44 (14,6%) пациентов. Сочетание позитивности по АЦА и анти-Scl-70 было отмечено у трех пациентов с лимитированной ССД, в том числе у одной – с ранней формой заболевания. Позитивными по анти-UI-РНП были 26 больных. Среди них преобладали пациенты с лимитированной и перекрестной формами ССД. Анти-РНКП III обнаруживались в 5,5% случаев, преимущественно в группе пациентов с лимитированной формой ССД; в одном случае они выявлены у больного с диффузным поражением кожи и выраженным интерстициальным поражением легких. Поражения почек в данной группе пациентов не отмечалось.</p></sec><sec><title>Заключение</title><p>Заключение. Особенностями российской когорты являются преобладание лимитированной формы ССД и частое выявление анти-Scl-70 как при диффузной, так и при лимитированной форме ССД; отсутствие корреляций анти-Scl-70 с быстрым прогрессированием патологического процесса, патологией почек. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective: to estimate frequency of autoantibodies in a cohort of Russian patients with systemic sclerosis (SS) and to investigate clinical associations of these autoantibodies.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. In 2012 to 2015, the investigation enrolled 300 patients (58 men and 242 women) who fulfilled the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) SS criteria. All patients underwent immunological examination including determination of antinuclear antibodies, anti-topoisomerase I (anti-Scl-70) antibodies, anti-centromere antibodies (ACA), anti-U1-ribonucleoprotein antibodies (anti-U1 RNP), and anti-RNP III antibodies.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The vast majority of patients were middle-aged females with moderate disease duration. There was a preponderance of patients with limited cutaneous form (55.3%); 37.4% patients had diffuse SS; 5.9% had overlap syndrome; and &lt;1% had visceral and juvenile SS. The vast majority (83.8%) of patients were found to have antinuclear factor. Among the SS-associated antibodies, anti-Scl-70 were most common and were revealed in approximately one-half of the patients. ACA was present in only 44 (14.6%) patients. There was a combination of positivity for ACA and anti-Scl-70 antibodies in 3 patients with limited cutaneous SS, including one with an early form of the disease. 26 patients had anti-U1 RNP antibodies. Among them, there was a preponderance of patients with limited cutaneous SS and overlap syndrome. Anti-RNP III antibodies were found in 5.5% of cases, mainly in those with limited cutaneous SS; these were observed in one patient with diffuse SS and interstitial lung disease. No kidney injury was seen in this patient group.</p></sec><sec><title>Conclusion</title><p>Conclusion. The characteristics of the Russian cohort are the preponderance of the limited cutaneous SS and the frequent detection of anti-Scl-70 antibodies in both diffuse and limited cutaneous SS; no correlation of anti-Scl-70 antibodies with rapid progression of the pathological process, with kidney disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>системная склеродермия</kwd><kwd>лимитированная форма</kwd><kwd>диффузная форма</kwd><kwd>аутоантитела</kwd><kwd>ассоциации</kwd></kwd-group><kwd-group xml:lang="en"><kwd>systemic sclerosis</kwd><kwd>limited cutaneous form</kwd><kwd>diffuse form</kwd><kwd>autoantibodies</kwd><kwd>associations</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ананьева ЛП, Александрова ЕН. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99 [Ananyeva LP, Aleksandrova EN. Autoantibodies in systemic sclerosis: spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.)]. doi: 10.14412/1995-4484-2016-86-99</mixed-citation><mixed-citation xml:lang="en">Ананьева ЛП, Александрова ЕН. Аутоантитела при системной склеродермии: спектр, клинические ассоциации и прогностическое значение. Научно-практическая ревматология. 2016;54(1):86-99 [Ananyeva LP, Aleksandrova EN. Autoantibodies in systemic sclerosis: spectrum, clinical associations, and prognostic value. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(1):86-99 (In Russ.)]. doi: 10.14412/1995-4484-2016-86-99</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kuwana М, Gabrielli A. Autoantibodies, autoimmunity. In: Hachulla E, Czirjak L, editors. EULAR Textbook on systemic sclerosis. London: BMJ; 2013. P. 88-96.</mixed-citation><mixed-citation xml:lang="en">Kuwana М, Gabrielli A. Autoantibodies, autoimmunity. In: Hachulla E, Czirjak L, editors. EULAR Textbook on systemic sclerosis. London: BMJ; 2013. P. 88-96.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mayes MD, Reveille JD. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams &amp; Williams; 2004. P. 1-17.</mixed-citation><mixed-citation xml:lang="en">Mayes MD, Reveille JD. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams &amp; Williams; 2004. P. 1-17.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Subcommittee for scleroderma criteria of the American Rhеumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rhеum. 1980;23(5):581-90.</mixed-citation><mixed-citation xml:lang="en">Subcommittee for scleroderma criteria of the American Rhеumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rhеum. 1980;23(5):581-90.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan S, Maurer B, Distler O. Performance of the new EULAR /ACR classification criteria for systemic sclerosis in clinical practice. Ann Rhеum Dis. 2013;72 Suppl 3:60.</mixed-citation><mixed-citation xml:lang="en">Jordan S, Maurer B, Distler O. Performance of the new EULAR /ACR classification criteria for systemic sclerosis in clinical practice. Ann Rhеum Dis. 2013;72 Suppl 3:60.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hamaguchi Y. Autoantibodies and their clinical characteristics in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):139-47. doi: 10.2177/jsci.36.139</mixed-citation><mixed-citation xml:lang="en">Hamaguchi Y. Autoantibodies and their clinical characteristics in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):139-47. doi: 10.2177/jsci.36.139</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340-54. doi:10.1016/j.autrev.2012.05.011</mixed-citation><mixed-citation xml:lang="en">Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340-54. doi:10.1016/j.autrev.2012.05.011</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mierau R, Genth E. [Scleroderma associated autoantibodies - clinical and diagnostic relevance]. Z Rheumatol. 2006 Jul;65(4):279-84 (In Germ.). doi: 10.1007/s00393-006-0067-y</mixed-citation><mixed-citation xml:lang="en">Mierau R, Genth E. [Scleroderma associated autoantibodies - clinical and diagnostic relevance]. Z Rheumatol. 2006 Jul;65(4):279-84 (In Germ.). doi: 10.1007/s00393-006-0067-y</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010 Jan;37(1):42-53. doi: 10.1111/j.1346-8138.2009.00762.x</mixed-citation><mixed-citation xml:lang="en">Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010 Jan;37(1):42-53. doi: 10.1111/j.1346-8138.2009.00762.x</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gallucio F, Walker U, Nihtyaova S, et al. Registries in systemic sclerosis: a worldwide experience. Rheumatology. 2011;50:60-8. doi: 10.1093/rheumatology/keq355</mixed-citation><mixed-citation xml:lang="en">Gallucio F, Walker U, Nihtyaova S, et al. Registries in systemic sclerosis: a worldwide experience. Rheumatology. 2011;50:60-8. doi: 10.1093/rheumatology/keq355</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade LEC, Bortoluzzo AB, Bica BEG, et al. Immunological profile in systemic sclerosis: analysis of 1139 brazilian patients. Ann Rhem Dis. 2007;66 Suppl 11:198.</mixed-citation><mixed-citation xml:lang="en">Andrade LEC, Bortoluzzo AB, Bica BEG, et al. Immunological profile in systemic sclerosis: analysis of 1139 brazilian patients. Ann Rhem Dis. 2007;66 Suppl 11:198.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J, Assassi S, Guo G, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Autoimmun Rev. 2013 Jan;12(3):340-54. doi: 10.1016/j.autrev.2012.05.011. Epub 2012 Jun 25.</mixed-citation><mixed-citation xml:lang="en">Wang J, Assassi S, Guo G, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Autoimmun Rev. 2013 Jan;12(3):340-54. doi: 10.1016/j.autrev.2012.05.011. Epub 2012 Jun 25.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Morozzi G, Bellisai F, Fineschi I, et al. Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. Auto Immun Highlights. 2011 Mar 23;2(1):29-33. doi: 10.1007/s13317- 011-0015-y. eCollection 2011.</mixed-citation><mixed-citation xml:lang="en">Morozzi G, Bellisai F, Fineschi I, et al. Prevalence of anti-histone antibodies, their clinical significance and correlation with other autoantibodies in a cohort of Italian scleroderma patients. Auto Immun Highlights. 2011 Mar 23;2(1):29-33. doi: 10.1007/s13317- 011-0015-y. eCollection 2011.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Radic M, Martinovic Kaliterna D, Ljutic D, et al. The level of anti-topoisomerase I antibodies correlates with the severity of metacarpophalangeal and proximal interphalangeal jonts flexion contractures in patients with systemic sclerosis. Ann Rhem Dis. 2007;66 Suppl 11:221.</mixed-citation><mixed-citation xml:lang="en">Radic M, Martinovic Kaliterna D, Ljutic D, et al. The level of anti-topoisomerase I antibodies correlates with the severity of metacarpophalangeal and proximal interphalangeal jonts flexion contractures in patients with systemic sclerosis. Ann Rhem Dis. 2007;66 Suppl 11:221.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Respico GR, Malhotra A, et al. Autoantibodies as risk factors for malignancy in systemic sclerosis. Ann Rhem Dis. 2007;66 Suppl 11:222.</mixed-citation><mixed-citation xml:lang="en">Respico GR, Malhotra A, et al. Autoantibodies as risk factors for malignancy in systemic sclerosis. Ann Rhem Dis. 2007;66 Suppl 11:222.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Boin А, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep. 2007;9:165-72. doi: 10.1007/s11926-007-0012-3</mixed-citation><mixed-citation xml:lang="en">Boin А, Rosen A. Autoimmunity in systemic sclerosis: current concepts. Curr Rheumatol Rep. 2007;9:165-72. doi: 10.1007/s11926-007-0012-3</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Walker UA, Tyndall A, Czirjak L, et al., EUSTAR Co-authors. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis. Epub 2007 Feb 1. doi: 10.1136/ard.2006.062901</mixed-citation><mixed-citation xml:lang="en">Walker UA, Tyndall A, Czirjak L, et al., EUSTAR Co-authors. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis. Epub 2007 Feb 1. doi: 10.1136/ard.2006.062901</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hamaguchi Y. Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42-53. doi: 10.1111/j.1346- 8138.2009.00762.x</mixed-citation><mixed-citation xml:lang="en">Hamaguchi Y. Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42-53. doi: 10.1111/j.1346- 8138.2009.00762.x</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Satoh T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxf). 2009;48(23):1570-4. doi: 10.1093/rheumatology/kep290</mixed-citation><mixed-citation xml:lang="en">Satoh T, Ishikawa O, Ihn H, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxf). 2009;48(23):1570-4. doi: 10.1093/rheumatology/kep290</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
